1,366 results on '"Pantuck, Allan J."'
Search Results
2. MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study
Catalog
Books, media, physical & digital resources
3. ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review
4. Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting
5. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
6. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial
7. Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines
8. Gene and Protein Expression of MAGE and Associated Immune Landscape Elements in Non-Small-Cell Lung Carcinoma and Urothelial Carcinomas.
9. Impact of immune checkpoint inhibitor-based combination therapy on palliative care utilization for patients with metastatic renal cell carcinoma.
10. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
11. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results
12. Living with Metastatic Renal Cell Carcinoma: Survivorship Needs in the Combination Therapy Era
13. INITIAL FINDINGS FROM THE MULTI-INSTITUTIONAL SARCOMATOID RENAL CELL CARCINOMA CONSORTIUM (SaRCC)
14. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
15. Chapter 34 - Clinical trials: Getting started
16. Association of tumor grade, enhancement on multiphasic CT and microvessel density in patients with clear cell renal cell carcinoma
17. Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients
18. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial
19. The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
20. Pomegranate extract inhibits EMT in clear cell renal cell carcinoma in a NF-κB and JNK dependent manner.
21. Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma
22. Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?
23. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era
24. A Double-Blind, Randomized, Neoadjuvant Study of the Tissue Effects of POMx Pills in Men with Prostate Cancer Before Radical Prostatectomy
25. Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma
26. A Novel Multiplex Assay Combining Autoantibodies Plus PSA Has Potential Implications for Classification of Prostate Cancer from Non-malignant Cases
27. Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma
28. Sarcomatoid Renal Cell Carcinoma and Collecting Duct Carcinoma: Discrimination From Common Renal Cell Carcinoma Subtypes and Benign RCC Mimics on Multiphasic MDCT
29. Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility
30. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma
31. Collecting Duct Carcinoma and Renal Medullary Carcinoma
32. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art
33. Clear cell renal cell carcinoma: identifying PTEN expression on multiphasic MDCT
34. Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy
35. Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression
36. Trends in urinary diversion after radical cystectomy for urothelial carcinoma
37. The Role of Adrenalectomy in Renal Cancer
38. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
39. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort
40. Supplementary Figures 1-3. Supplmentary Tables 1-4. Supplementary Materials and Methods. from MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer
41. Data from MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer
42. LBA03-01 89 Zr-DFO-GIRENTUXIMAB FOR PET/CT IMAGING OF INDETERMINATE RENAL MASSES–RESULTS FROM PHASE 3 ZIRCON STUDY
43. Data from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
44. Table S2 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
45. Supplementary Figure 2 from A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
46. Supplementary Figure 1 from A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
47. Supplementary Table 1 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
48. Supplementary Figure 3 from A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
49. Supplementary Table 2 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
50. Supplementary Figure 1 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.